1. Home
  2. TSBX vs CYCN Comparison

TSBX vs CYCN Comparison

Compare TSBX & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSBX
  • CYCN
  • Stock Information
  • Founded
  • TSBX 2015
  • CYCN 2018
  • Country
  • TSBX United States
  • CYCN United States
  • Employees
  • TSBX N/A
  • CYCN N/A
  • Industry
  • TSBX
  • CYCN Biotechnology: Pharmaceutical Preparations
  • Sector
  • TSBX
  • CYCN Health Care
  • Exchange
  • TSBX Nasdaq
  • CYCN Nasdaq
  • Market Cap
  • TSBX 8.4M
  • CYCN 7.5M
  • IPO Year
  • TSBX 2023
  • CYCN N/A
  • Fundamental
  • Price
  • TSBX $0.38
  • CYCN $2.61
  • Analyst Decision
  • TSBX Buy
  • CYCN
  • Analyst Count
  • TSBX 3
  • CYCN 0
  • Target Price
  • TSBX $4.75
  • CYCN N/A
  • AVG Volume (30 Days)
  • TSBX 128.8K
  • CYCN 31.9K
  • Earning Date
  • TSBX 05-12-2025
  • CYCN 03-04-2025
  • Dividend Yield
  • TSBX N/A
  • CYCN N/A
  • EPS Growth
  • TSBX N/A
  • CYCN N/A
  • EPS
  • TSBX N/A
  • CYCN N/A
  • Revenue
  • TSBX N/A
  • CYCN $2,000,000.00
  • Revenue This Year
  • TSBX N/A
  • CYCN N/A
  • Revenue Next Year
  • TSBX N/A
  • CYCN N/A
  • P/E Ratio
  • TSBX N/A
  • CYCN N/A
  • Revenue Growth
  • TSBX N/A
  • CYCN N/A
  • 52 Week Low
  • TSBX $0.34
  • CYCN $1.27
  • 52 Week High
  • TSBX $3.88
  • CYCN $9.47
  • Technical
  • Relative Strength Index (RSI)
  • TSBX 44.54
  • CYCN 47.14
  • Support Level
  • TSBX $0.37
  • CYCN $2.44
  • Resistance Level
  • TSBX $0.42
  • CYCN $2.85
  • Average True Range (ATR)
  • TSBX 0.04
  • CYCN 0.20
  • MACD
  • TSBX 0.00
  • CYCN 0.02
  • Stochastic Oscillator
  • TSBX 37.25
  • CYCN 35.68

About TSBX Turnstone Biologics Corp.

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Share on Social Networks: